Skip to main content

Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease

European Journal of Clinical Pharmacology volume 41, pages 463–466 (1991)Cite this article

Summary

The influence of age on the kinetics of a standard oral dose of levodopa administered with an inhibitor of peripheral dopa decarboxylase enzymes (benserazide) has been evaluated in 40 patients with Parkinson's disease (age 34–78 y) on chronic therapy. They were divided into 2 groups, on the basis of age below (21 patients, Group A) or above (19 patients, Group B) 65 y.

The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 μmol·1−1·min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml·min−1 ·kg−1) and a longer plasma elimination half-life (67.6 versus 54.6 min). The age of the patients was positively correlated with the AUC of levodopa (r=0.474) and its plasma elimination half-life (r=0.391), and was negatively correlated with clearance (r=−0.489).

The findings confirm previous data on volunteers that showed a reduction in the systemic clearance of levodopa due to age, which would probably account for the finding of a greater AUC of levodopa in older patients. The observed, age-mediated differences in levodopa pharmacokinetics, albeit statistically significant, were moderate and were likely to be of only minor importance for the dosing schedule.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Nutt JG, Fellmann JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7: 35–49

    Google Scholar 

  2. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS (1976) Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of Parkinsonism. Drugs 11: 329–377

    Google Scholar 

  3. Evans MA, Triggs EJ, Broe GA, Saines N (1980) Systemic availability of orally administered L-dopa in the elderly Parkinsonian patient. Eur J Clin Pharmacol 17: 215–221

    Google Scholar 

  4. Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in presence of carbidopa. Br J Clin Pharmacol 28: 61–69

    Google Scholar 

  5. Contin M, Riva R, Martinelli P, Procaccianti G, Cortelli P, Avoni P, Baruzzi A (1990) Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 13: 19–28

    Google Scholar 

  6. Algeri S, Cerletti C, Curcio M, Morselli PL, Bonolo L, Buniva G, Minazzi M, Minoli G (1976) Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man. Eur J Clin Pharmacol 35: 293–299

    Google Scholar 

  7. Contin M, Riva R, Martinelli P, Procaccianti G, Albani F, Baruzzi A (1991) Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: effect on levodopa bioavailability. Clin Neuropharmacol 14: 148–155

    Google Scholar 

  8. Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N (1975) Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 25: 1029–1034

    Google Scholar 

  9. Massoud N (1984) Pharmacokinetic considerations in geriatric patients. In: Benet LZ, Massoud N, Gambertoglio JG (eds) Pharmacokinetic basis for drug treatment. Raven, New York, pp 283–310

    Google Scholar 

  10. Schmucker DL (1985) Aging and drug disposition: an update. Pharmacol Rev 37: 133–148

    Google Scholar 

  11. Pincus JH, Barry K (1987) Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 44: 270–272

    Google Scholar 

  12. Baruzzi A, Contin M, Albani F, Riva R (1986) Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 375: 165–169

    Google Scholar 

  13. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442

    Google Scholar 

  14. Abrams WB, Coutinho CB, Leon AS, Spiegel HE (1971) Absorption and metabolism of levodopa. JAMA 218: 1912–1914

    Google Scholar 

  15. Andersson I, Granerus AK, Jagenburg R, Svanborg A (1975) Intestinal decarboxylation of orally administered L-dopa. Acta Med Scand 198: 415–420

    Google Scholar 

  16. Cotler S, Holazo A, Boxenbaum HG, Kaplan SA (1976) Influence of route of administration on physiological availability of levodopa in dogs. J Pharm Sci 65: 822–827

    Google Scholar 

  17. Iwamoto K, Watanabe J, Yamada M, Atsumi F, Matsushita T (1987) Effect of age on gastrointestinal and hepatic first-pass effects on levodopa in rats. J Pharm Pharmacol 39: 421–425

    Google Scholar 

  18. Gancher ST, Nutt JG, Woodward WR (1987) Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 37: 940–944

    Google Scholar 

  19. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Paull PD (1981) Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 31: 1288–1294

    Google Scholar 

  20. Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13: 179–190

    Google Scholar 

  21. Reilly DK, Rivera-Calimlim L, Van Dyke D (1980) Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 28: 278–286

    Google Scholar 

  22. Pilling JB, Baker J, Iversen LL, Iversen SD, Robbins T (1975) Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine. J Neurol Neurosurg Psychiat 38: 129–135

    Google Scholar 

  23. Bentué-Ferrer D, Allain H, Reymann JM, Sabouraud O, Van den Driessche J (1988) Lack of pharmacokinetic influence on levodopa by bromocriptine. Clin Neuropharmacol 11: 83–86

    Google Scholar 

  24. Sutton JP, Goetz CG, Buhrfiend C, Carvey PM (1990) Levodopa pharmacokinetics and dopamine agonist cotherapy. Neurology 40 [Suppl 1]: 263

    Google Scholar 

  25. Wilson K (1984) Sex-related differences in drug disposition in man. Clin Pharmacokinet 9: 189–202

    Google Scholar 

Download references

Author information

Affiliations

  1. Laboratory of Neuropharmacology, Institute of Neurology, University of Bologna, Bologna, Italy

    M. Contin, R. Riva, P. Martinelli, F. Albani & A. Baruzzi

Authors
  1. M. Contin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Riva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Albani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Baruzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was part of the “Progetto finalizzato Invecchiamento” of the National Research Council of Italy, Grant No. 912012

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Contin, M., Riva, R., Martinelli, P. et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 41, 463–466 (1991). https://doi.org/10.1007/BF00626370

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00626370

Key words

  • Levodopa
  • Pharmacokinetics
  • Parkinson's disease
  • age